NCT00263822 2013-08-27
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed